FindTrial
Sign In

3,4-diaminopyridine

DRUG11 trials

Sponsors

Fukushima Medical University, Tokushima University, FDA Office of Orphan Products Development, Assistance Publique - Hôpitaux de Paris, University of Aarhus

Conditions

BotulismCongenital Myasthenia (CM)Congenital Myasthenic SyndromeFatigueLambert Eaton Myasthenic Syndrome (LEMS)Lambert-Eaton Myasthenic SyndromeLambert-Eaton Myasthenic Syndrome (LEMS)Lambert-Eaton myasthenic syndrome

Phase 2

Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation
CompletedNCT00342381
University of AarhusFatigue, Multiple Sclerosis
Start: 2006-06-30End: 2007-12-31Target: 120Updated: 2007-12-17
Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin
Active, not recruitingJPRN-UMIN000004795
Fukushima Medical UniversityLambert-Eaton myasthenic syndrome
Start: 2010-01-01Target: 5Updated: 2026-06-29
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
CompletedNCT01441557
Centre Hospitalier Universitaire, AmiensBotulism
Start: 2011-09-30End: 2012-03-31Updated: 2025-09-19

Phase 3

Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
CompletedNCT00190268
Assistance Publique - Hôpitaux de ParisMultiple Sclerosis
Start: 2005-02-28End: 2008-06-30Updated: 2011-02-21

Unknown Phase

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
CompletedNCT00004832
FDA Office of Orphan Products DevelopmentLambert-Eaton Myasthenic Syndrome
Start: 1994-08-31End: 1998-06-30Target: 26Updated: 2015-03-25
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
NCT00872950
Lahey ClinicCongenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Updated: 2022-04-11
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
NCT01378546
Louis H. Weimer, MDLambert Eaton Myasthenic Syndrome (LEMS)
Start: 2005-05-31Updated: 2013-07-18
Treatment Use of 3,4-Diaminopyridine
NCT01765140
Vern C. Juel, M.D.Myasthenic Syndromes, Congenital
Updated: 2025-01-20
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
NCT02012933
Oregon Health and Science UniversityCongenital Myasthenia (CM), Lambert-Eaton Myasthenic Syndrome (LEMS)
Updated: 2019-12-11
Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin
RecruitingJPRN-UMIN000024055
Tokushima UniversityLambert-Eaton myasthenic syndrome
Start: 2016-11-01Target: 10Updated: 2026-06-29
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
NCT03062631
Ricardo MaselliCongenital Myasthenic Syndrome
Updated: 2023-06-02